BioInformant

Your Global Leader in Stem Cell Market Research

You are here: Home / Archives for news

Cellerant Therapeutics Awarded 20th RMAT in U.S.

By Leave a Comment

Cellerant Therapeutics RMATOn July 2nd, 2018, Cellerant Therapeutics was awarded a Regenerative Medicine Advanced Therapy (RMAT) designation for romyelocel-L (human myeloid progenitor cells) by the U.S. FDA. The treatment is used for the “prevention of serious bacterial and fungal infections in patients with de novo acute myeloid leukemia (AML) undergoing induction chemotherapy.”

Cellerant RMAT Designation

Romyelocel- is a universal, off-the-shelf cell therapy, because it does not require HLA matching between patient and donor. Neutropenia is a major side effect of myelosuppressive chemotherapies, including induction therapy. This can endanger patients by placing them at risk for life-threatening infections.

According to Ram Mandalam, President and CEO of Cellerant, “Receiving RMAT designation for romyelocel-L is an important milestone and recognition by the FDA of the potential of romyelocel-L to serve this unmet medical need.” [Read more…]

Minerva Biotechnologies, Interview with CEO Dr. Cynthia Bamdad

By

Minerva Biotechnologies is a regenerative medicine company specializing in stem cell therapeutics that is developing cancer immunotherapies to target 75% of solid tumors and to prevent cancer metastasis. I had the honor of interviewing Cynthia Bamdad, PhD, CEO of Minerva Biotechnologies. In this interview, we discuss Minerva’s technology platform, product portfolio, IP strategy, and strategic goals. We also explore the significance of the company’s recently launched AlphaSTEM™ Culture System that is a simple method for inducing the naïve state in human stem cells. Enjoy! [Read more…]

5 Trends Impacting the Cord Blood Industry

By

The cord blood industry came into existence in the early 1990’s with the formation of several leading cord blood banks in the U.S., followed by the formation of cord blood banks across the globe. It has now been almost 40 years since it was first proposed that stem and progenitor cells were present in human cord blood, so the question is, what will the next 40 years hold for the cord blood banking industry?

The last few years have been marked by substantial change, as explored below. [Read more…]

Cord Blood Industry is “Consolidating and Maturing”

By

Within the cord blood industry, there was a strong growth period during the 2000’s. However, over the past few years, the market has substantially matured and consolidated. While strong industry growth continues within North Asia (particularly China, Hong Kong, and Taiwan) and Southeast Asia (led by India and Malaysia), growth of the North American market is flat and the European cord blood banking market is declining. [Read more…]

BioInformant's World-Class Clients